Zobrazeno 1 - 10
of 406
pro vyhledávání: '"Kevin J, Anstrom"'
Autor:
Javed Butler, Muhammad Shahzeb Khan, Tomasz Gasior, Tyler R. Erickson, Vanja Vlajnic, Frank Kramer, Robert O. Blaustein, David Goldsbury, Lothar Roessig, Carolyn S.P. Lam, Kevin J. Anstrom, Paul W. Armstrong, for the VITALITY Study Group
Publikováno v:
ESC Heart Failure, Vol 11, Iss 1, Pp 293-298 (2024)
Abstract Aims The relationship between accelerometry data and changes in Kansas City Cardiomyopathy Questionnaire‐Physical Limitation Score (KCCQ‐PLS) or 6 min walk test (6MWT) is not well understood. Methods and results VITALITY‐HFpEF accelero
Externí odkaz:
https://doaj.org/article/f04a2a3da67145508514c0b3ac19532a
Autor:
Dan-Yu Lin, Jianqiao Wang, Kevin J. Anstrom, Lisa M. LaVange, Jun Wen, Samuel A. Bozzette, William G. Powderly
Publikováno v:
International Journal of Infectious Diseases, Vol 146, Iss , Pp 107168- (2024)
A randomized, double-blind, placebo-controlled clinical trial was conducted to investigate the efficacy of infliximab, abatacept, and cenicriviroc in treating patients hospitalized with COVID-19. The patient's clinical status was assessed daily on an
Externí odkaz:
https://doaj.org/article/827459dd2b844af788b38f46c08cb2d8
Autor:
Eric L. Eisenstein, Kevin D. Hill, Nancy Wood, Jerry L. Kirchner, Kevin J. Anstrom, Christopher B. Granger, Sunil V. Rao, H. Scott Baldwin, Jeffrey P. Jacobs, Marshall L. Jacobs, Prince J. Kannankeril, Eric M. Graham, Sean M. O'Brien, Jennifer S. Li
Publikováno v:
Contemporary Clinical Trials Communications, Vol 38, Iss , Pp 101257- (2024)
Background: Registry-based trials have the potential to reduce randomized clinical trial (RCT) costs. However, observed cost differences also may be achieved through pragmatic trial designs. A systematic comparison of trial costs across different des
Externí odkaz:
https://doaj.org/article/7912ef2ef50e4a909f9255670edbac5b
Autor:
Susanna Naggie, Aaron Milstone, Mario Castro, Sean P. Collins, Seetha Lakshmi, Deverick J. Anderson, Lizbeth Cahuayme-Zuniga, Kisha Batey Turner, Lauren W. Cohen, Judith Currier, Elizabeth Fraulo, Anne Friedland, Jyotsna Garg, Anoop George, Hillary Mulder, Rachel E. Olson, Emily C. O'Brien, Russell L. Rothman, Elizabeth Shenkman, Jack Shostak, Christopher W. Woods, Kevin J. Anstrom, Adrian F. Hernandez
Publikováno v:
International Journal of Infectious Diseases, Vol 129, Iss , Pp 40-48 (2023)
ABSTRACT: Objectives: To determine whether hydroxychloroquine (HCQ) is safe and effective at preventing COVID-19 infections among health care workers (HCWs). Methods: In a 1: 1 randomized, placebo-controlled, double-blind, parallel-group, superiority
Externí odkaz:
https://doaj.org/article/1b8ea14072a44cb1b9ca525f0f41fbe4
Autor:
Adrian F Hernandez, David R Boulware, Radha Rajasingham, Christopher W Woods, Kevin J Anstrom, Ravi Amaravadi, Benjamin S Abella, Hwanhee Hong, Anne Friedland, Mengyi Hu, Susan Halabi, John E McKinnon, Jorge Rojas-Serrano, Angélica Margarita Portillo-Vázquez, Susanna Naggie
Publikováno v:
BMJ Open, Vol 13, Iss 6 (2023)
Objective We studied the safety and efficacy of hydroxychloroquine (HCQ) as pre-exposure prophylaxis for COVID-19 in healthcare workers (HCWs), using a meta-analysis of randomised controlled trials (RCTs).Data sources PubMed and EMBASE databases were
Externí odkaz:
https://doaj.org/article/10d79c6e96d6445e963962280b7084b7
Autor:
Emily P. Zeitler, Yanhong Li, Adam P. Silverstein, Andrea M. Russo, Jeanne E. Poole, Melanie R. Daniels, Hussein R. Al‐Khalidi, Kerry L. Lee, Tristram D. Bahnson, Kevin J. Anstrom, Douglas L. Packer, Daniel B. Mark
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 3 (2023)
Background Women with atrial fibrillation (AF) demonstrate more AF‐related symptoms and worse quality of life (QOL). Whether increased use of ablation in women reduces sex‐related QOL differences is unknown. Sex‐related outcomes for ablation ve
Externí odkaz:
https://doaj.org/article/3b669f2b93534eb687b682a18fc931be
Autor:
Nancy Luo, MD, MHS, Christopher M. O'Connor, MD, Karen Chiswell, PhD, Kevin J. Anstrom, PhD, L. Kristin Newby, MD, MHS, Robert J. Mentz, MD
Publikováno v:
CJC Open, Vol 3, Iss 11, Pp 1333-1340 (2021)
Background: Prior studies suggest similar long-term mortality rates for patients with heart failure (HF) with preserved ejection fraction (HFpEF) vs reduced ejection fraction. However, although coronary heart disease (CHD) is associated with worse pr
Externí odkaz:
https://doaj.org/article/6738d01874e04caa85a41cfa1501d83c
Autor:
Filippo Ravalli, Xavier Vela Parada, Francisco Ujueta, Rachel Pinotti, Kevin J. Anstrom, Gervasio A. Lamas, Ana Navas‐Acien
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 6 (2022)
Background EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD). Although a large randomized clinical trial showed benefit,
Externí odkaz:
https://doaj.org/article/81e4ded94d3a4a349532185c9fc9a958
Autor:
Kevin J. Anstrom, Imre Noth, Kevin R. Flaherty, Rex H. Edwards, Joan Albright, Amanda Baucom, Maria Brooks, Allan B. Clark, Emily S. Clausen, Michael T. Durheim, Dong-Yun Kim, Jerry Kirchner, Justin M. Oldham, Laurie D. Snyder, Andrew M. Wilson, Stephen R. Wisniewski, Eric Yow, Fernando J. Martinez, For the CleanUP-IPF Study Team
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-13 (2020)
Abstract Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response. Moreover, prior therapeutic trials have suggested imp
Externí odkaz:
https://doaj.org/article/80a5ba602574475aac8d232860331806
Autor:
Carolyn S. P. Lam, Hillary Mulder, Yuri Lopatin, Jose B. Vazquez‐Tanus, David Siu, Justin Ezekowitz, Burkert Pieske, Christopher M. O’Connor, Lothar Roessig, Mahesh J. Patel, Kevin J. Anstrom, Adrian F. Hernandez, Paul W. Armstrong
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 10, Iss 22 (2021)
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, so
Externí odkaz:
https://doaj.org/article/746573cb9e5446779c083cce06f77a82